Research programme: CD47 antigen modulators - Paradigm Shift Therapeutics

Drug Profile

Research programme: CD47 antigen modulators - Paradigm Shift Therapeutics

Alternative Names: PSTx 23

Latest Information Update: 01 Oct 2016

Price : $50

At a glance

  • Originator National Cancer Institute (USA); Paradigm Shift Therapeutics
  • Developer National Center for Advancing Translational Sciences; Paradigm Shift Therapeutics
  • Class Small molecules
  • Mechanism of Action CD47 antigen inhibitors; CD47 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer
  • Research Cancer; Radioprotection

Most Recent Events

  • 29 Sep 2016 Early research in Radioprotection in USA (unspecified route) before September 2016
  • 29 Sep 2016 Preclinical trials in Breast cancer in USA (unspecified route)
  • 30 Sep 2015 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top